Objectives The purpose of this research was to study long term left ventricul ar(LV) adaptations in very high level endurance athletes. Background Knowledge of cardiac changes in athletes, who are at particularly high...Objectives The purpose of this research was to study long term left ventricul ar(LV) adaptations in very high level endurance athletes. Background Knowledge of cardiac changes in athletes, who are at particularly high risk of sudden car diac death, is mandatory to detect hypertrophic cardiomyopathy (HCM) or dilated (DCM) cardiomyopathy. Methods We carried out echocardiographic examinations on 2 86 cyclists(group A) and 52 matched sedentary volunteers (group C); 148 cyclists participated in the 1995 “Tour de France”race (group A1), 138 in the 1998 rac e (group A2), and 37 in both (group B). Results In groups A, A1, A2, and C, resp ectively, diastolic left ventricular diameter (LVID)was 60.1±3.9 mm, 59.2±3.8 mm, 61.0±3.9 mm, and 49.0 ±4.3 mm (A vs. C and A1 vs. A2, p< 0.0001), and maxi mal wall thickness (WT) was 11.1 ±1.3 mm, 11.6 ±1.3 mm, 10.6 ±1.1 mm, and 8.6 ±1.0 mm (A vs. C and A1 vs. A2, p< 0.0001). Among group A, 147 (51.4%) had LV ID >60 mm; 17 of them had also a below normal (< 52%) left ventricular ejection fraction (LVEF). Wall thickness exceeded 13 mm in 25 athletes (8.7%) (always< 15 mm), 23 with LVID >55 mm. In group B, LVID increased (58.3 ±4.8 mm to 60.3 ±4.2 mm, p< 0.001) and WT decreased (11.8 ±1.2 mm to 10.8 ±1.2 mm, p< 0.001) with time. Conclusions Over one half of these athletes exhibited unusual LV dil ation, along with a reduced LVEF in 11.6%(17 of 147), compatible with the diagn osis of DCM. Increased WT was less common (always <15 mm) and scarce without LV dilation (< 1%), eliminating the diagnosis of HCM. Serial examinations showed evidence of furth er LV dilation along with wall thinning. These results might have important impl ications for screening in athletes.展开更多
目的探讨生脉注射液联合重组人脑利钠肽治疗急性心力衰竭的临床效果。方法选取2014年1月—2017年10月在中国人民解放军第二五四医院收治的112例急性心力衰竭患者,随机分为对照组和治疗组,每组各56例。对照组静脉滴注注射用重组人脑利钠...目的探讨生脉注射液联合重组人脑利钠肽治疗急性心力衰竭的临床效果。方法选取2014年1月—2017年10月在中国人民解放军第二五四医院收治的112例急性心力衰竭患者,随机分为对照组和治疗组,每组各56例。对照组静脉滴注注射用重组人脑利钠肽,首次静脉冲击1.5μg/kg,随后按照0.01μg/(kg·min)静脉泵入。治疗组在对照组治疗基础上静脉滴注生脉注射液,50 m L生脉注射液加入到5%葡萄糖注射液100 m L,1次/d。两组均连续治疗3 d。观察两组的临床疗效,比较两组治疗前后左心室射血分数(LVEF)、左室舒张末内径(LVEDD)、尿素氮(BUN)、肌酐(Cr)、血清脑钠肽(BNP)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为78.57%、94.64%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者LVEF显著升高,但LVEDD、BUN、Cr、BNP显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组LVEF高于对照组,LVEDD、BUN、Cr、BNP低于对照组,两组比较差异具有统计学意义(P<0.05)。结论生脉注射液联合重组人脑利钠肽治疗急性心力衰竭具有显著的临床治疗效果,可明显改善患者心功能,保护肾功能,具有一定的临床推广应用价值。展开更多
文摘Objectives The purpose of this research was to study long term left ventricul ar(LV) adaptations in very high level endurance athletes. Background Knowledge of cardiac changes in athletes, who are at particularly high risk of sudden car diac death, is mandatory to detect hypertrophic cardiomyopathy (HCM) or dilated (DCM) cardiomyopathy. Methods We carried out echocardiographic examinations on 2 86 cyclists(group A) and 52 matched sedentary volunteers (group C); 148 cyclists participated in the 1995 “Tour de France”race (group A1), 138 in the 1998 rac e (group A2), and 37 in both (group B). Results In groups A, A1, A2, and C, resp ectively, diastolic left ventricular diameter (LVID)was 60.1±3.9 mm, 59.2±3.8 mm, 61.0±3.9 mm, and 49.0 ±4.3 mm (A vs. C and A1 vs. A2, p< 0.0001), and maxi mal wall thickness (WT) was 11.1 ±1.3 mm, 11.6 ±1.3 mm, 10.6 ±1.1 mm, and 8.6 ±1.0 mm (A vs. C and A1 vs. A2, p< 0.0001). Among group A, 147 (51.4%) had LV ID >60 mm; 17 of them had also a below normal (< 52%) left ventricular ejection fraction (LVEF). Wall thickness exceeded 13 mm in 25 athletes (8.7%) (always< 15 mm), 23 with LVID >55 mm. In group B, LVID increased (58.3 ±4.8 mm to 60.3 ±4.2 mm, p< 0.001) and WT decreased (11.8 ±1.2 mm to 10.8 ±1.2 mm, p< 0.001) with time. Conclusions Over one half of these athletes exhibited unusual LV dil ation, along with a reduced LVEF in 11.6%(17 of 147), compatible with the diagn osis of DCM. Increased WT was less common (always <15 mm) and scarce without LV dilation (< 1%), eliminating the diagnosis of HCM. Serial examinations showed evidence of furth er LV dilation along with wall thinning. These results might have important impl ications for screening in athletes.
文摘目的探讨生脉注射液联合重组人脑利钠肽治疗急性心力衰竭的临床效果。方法选取2014年1月—2017年10月在中国人民解放军第二五四医院收治的112例急性心力衰竭患者,随机分为对照组和治疗组,每组各56例。对照组静脉滴注注射用重组人脑利钠肽,首次静脉冲击1.5μg/kg,随后按照0.01μg/(kg·min)静脉泵入。治疗组在对照组治疗基础上静脉滴注生脉注射液,50 m L生脉注射液加入到5%葡萄糖注射液100 m L,1次/d。两组均连续治疗3 d。观察两组的临床疗效,比较两组治疗前后左心室射血分数(LVEF)、左室舒张末内径(LVEDD)、尿素氮(BUN)、肌酐(Cr)、血清脑钠肽(BNP)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为78.57%、94.64%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者LVEF显著升高,但LVEDD、BUN、Cr、BNP显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组LVEF高于对照组,LVEDD、BUN、Cr、BNP低于对照组,两组比较差异具有统计学意义(P<0.05)。结论生脉注射液联合重组人脑利钠肽治疗急性心力衰竭具有显著的临床治疗效果,可明显改善患者心功能,保护肾功能,具有一定的临床推广应用价值。
